Published in Nat Med on November 07, 2011
The Effects of Glycine on Atherosclerosis and Metabolic Syndrome-related Parameters. | NCT03850314
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol (2013) 3.85
Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol (2012) 2.98
MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med (2014) 2.62
Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med (2015) 2.59
Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity (2013) 2.37
Role of extracellular RNA in atherosclerotic plaque formation in mice. Circulation (2013) 2.18
Medical hyperspectral imaging: a review. J Biomed Opt (2014) 2.07
Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol (2013) 1.97
Regulation of lipid stores and metabolism by lipophagy. Cell Death Differ (2012) 1.80
MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest (2012) 1.77
Artery Tertiary Lymphoid Organs Control Aorta Immunity and Protect against Atherosclerosis via Vascular Smooth Muscle Cell Lymphotoxin β Receptors. Immunity (2015) 1.74
Chronic variable stress activates hematopoietic stem cells. Nat Med (2014) 1.70
A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun (2014) 1.58
Deficiency of the sialyltransferase St3Gal4 reduces Ccl5-mediated myeloid cell recruitment and arrest: short communication. Circ Res (2014) 1.50
Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. PLoS One (2015) 1.48
Omega-3 fatty acids: mechanisms underlying 'protective effects' in atherosclerosis. Curr Opin Lipidol (2013) 1.46
Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest (2013) 1.43
Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. J Hematol Oncol (2013) 1.42
Cholesterol in the retina: the best is yet to come. Prog Retin Eye Res (2014) 1.27
Senescent cells: a novel therapeutic target for aging and age-related diseases. Clin Pharmacol Ther (2012) 1.25
The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem (2013) 1.22
S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease. Mediators Inflamm (2013) 1.18
Rheumatoid arthritis and cardiovascular disease. Am Heart J (2013) 1.14
Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med (2014) 1.12
Molecular imaging of inflammation in atherosclerosis. Theranostics (2013) 1.08
Progression of carotid intima-media thickness and coronary artery calcium over 6 years in an HIV-infected cohort. J Acquir Immune Defic Syndr (2013) 1.08
Inflammasomes and metabolic disorders: old genes in modern diseases. Mol Cell (2014) 1.06
Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science (2016) 1.05
Dynamic Aspects of Macrophage Polarization during Atherosclerosis Progression and Regression. Front Immunol (2014) 1.04
Diversity and specificity of the mitogen-activated protein kinase phosphatase-1 functions. Cell Mol Life Sci (2012) 1.03
MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2014) 1.03
Pharmacological actions and therapeutic applications of Salvia miltiorrhiza depside salt and its active components. Acta Pharmacol Sin (2012) 1.03
The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front Physiol (2014) 1.03
Links between ectopic fat and vascular disease in humans. Arterioscler Thromb Vasc Biol (2014) 1.02
Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol (2012) 1.02
Lysophosphatidic acid in atherosclerotic diseases. Br J Pharmacol (2012) 1.01
Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int (2014) 1.01
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev (2015) 1.00
Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK/mTOR signaling pathway. J Transl Med (2015) 0.99
Vascular endothelial growth factor signaling in hypoxia and inflammation. J Neuroimmune Pharmacol (2014) 0.99
The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol (2015) 0.98
Scan-rescan reproducibility of quantitative assessment of inflammatory carotid atherosclerotic plaque using dynamic contrast-enhanced 3T CMR in a multi-center study. J Cardiovasc Magn Reson (2014) 0.95
B cell subsets in atherosclerosis. Front Immunol (2012) 0.95
MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J Lipid Res (2013) 0.95
Risk of cardiovascular disease in a traditional African population with a high infectious load: a population-based study. PLoS One (2012) 0.94
Arrest Functions of the MIF Ligand/Receptor Axes in Atherogenesis. Front Immunol (2013) 0.94
Chemokines and microRNAs in atherosclerosis. Cell Mol Life Sci (2015) 0.94
Hypercholesterolemia links hematopoiesis with atherosclerosis. Trends Endocrinol Metab (2012) 0.94
Biological relevance of inflammation and oxidative stress in the pathogenesis of arterial diseases. Am J Pathol (2013) 0.92
Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes. Circ Res (2016) 0.92
The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance. J Immunol (2013) 0.92
Platelets and their chemokines in atherosclerosis-clinical applications. Front Physiol (2014) 0.91
Raised soluble P-selectin moderately accelerates atherosclerotic plaque progression. PLoS One (2014) 0.91
Macrophages in vascular inflammation--From atherosclerosis to vasculitis. Autoimmunity (2015) 0.91
Why targeting HDL should work as a therapeutic tool, but has not. J Cardiovasc Pharmacol (2013) 0.90
Inhibition of atherosclerosis-promoting microRNAs via targeted polyelectrolyte complex micelles. J Mater Chem B Mater Biol Med (2014) 0.90
Robust shifts in S100a9 expression with aging: a novel mechanism for chronic inflammation. Sci Rep (2013) 0.89
IL-1 and atherosclerosis: a murine twist to an evolving human story. J Clin Invest (2011) 0.89
Noncoding RNAs regulate NF-κB signaling to modulate blood vessel inflammation. Front Genet (2014) 0.89
VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis. Clin Exp Immunol (2014) 0.89
Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Rev Mol Diagn (2013) 0.88
C-reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells. Br J Pharmacol (2014) 0.88
PET/CT imaging of chemokine receptor CCR5 in vascular injury model using targeted nanoparticle. J Nucl Med (2014) 0.88
Myeloid cells in atherosclerosis: a delicate balance of anti-inflammatory and proinflammatory mechanisms. Curr Opin Lipidol (2013) 0.88
Lipid lowering and imaging protease activation in atherosclerosis. J Nucl Cardiol (2013) 0.88
High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano (2016) 0.87
Pro-Inflammatory Markers in Relation to Cardiovascular Disease in HIV Infection. A Systematic Review. PLoS One (2016) 0.87
Biochemical markers of aging for longitudinal studies in humans. Epidemiol Rev (2013) 0.87
Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies. Mediators Inflamm (2013) 0.87
Preclinical mouse models and methods for the discovery of the causes and treatments of atherosclerosis. Expert Opin Drug Discov (2012) 0.87
Antagonism of betulinic acid on LPS-mediated inhibition of ABCA1 and cholesterol efflux through inhibiting nuclear factor-kappaB signaling pathway and miR-33 expression. PLoS One (2013) 0.87
Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res (2016) 0.87
Concise review: therapeutic potential of adipose tissue-derived angiogenic cells. Stem Cells Transl Med (2012) 0.87
Plasmacytoid dendritic cells in atherosclerosis. Front Physiol (2012) 0.86
Functional analysis LRP6 novel mutations in patients with coronary artery disease. PLoS One (2014) 0.86
Genetic deletion of chemokine receptor Ccr7 exacerbates atherogenesis in ApoE-deficient mice. Cardiovasc Res (2012) 0.86
Nicotine potentiates proatherogenic effects of oxLDL by stimulating and upregulating macrophage CD36 signaling. Am J Physiol Heart Circ Physiol (2013) 0.85
Integrative DNA, RNA, and protein evidence connects TREML4 to coronary artery calcification. Am J Hum Genet (2014) 0.85
Clonal restriction and predominance of regulatory T cells in coronary thrombi of patients with acute coronary syndromes. Eur Heart J (2014) 0.85
Synergistic Effects of Chinese Herbal Medicine: A Comprehensive Review of Methodology and Current Research. Front Pharmacol (2016) 0.85
IL-6 in diabetes and cardiovascular complications. Br J Pharmacol (2014) 0.85
Disordered haematopoiesis and athero-thrombosis. Eur Heart J (2016) 0.85
IRGM1 regulates oxidized LDL uptake by macrophage via actin-dependent receptor internalization during atherosclerosis. Sci Rep (2013) 0.84
Association of MicroRNAs and YRNAs With Platelet Function. Circ Res (2015) 0.84
CXCR4 blockade induces atherosclerosis by affecting neutrophil function. J Mol Cell Cardiol (2014) 0.84
An eicosanoid-centric view of atherothrombotic risk factors. Cell Mol Life Sci (2012) 0.84
Apoptosis of THP-1 macrophages induced by protoporphyrin IX-mediated sonodynamic therapy. Int J Nanomedicine (2013) 0.84
Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see. J Nucl Cardiol (2012) 0.84
Hydrogen sulfide as a vasculoprotective factor. Med Gas Res (2013) 0.84
Gremlin-1 is an inhibitor of macrophage migration inhibitory factor and attenuates atherosclerotic plaque growth in ApoE-/- Mice. J Biol Chem (2013) 0.84
Potential therapeutic effects of mTOR inhibition in atherosclerosis. Br J Clin Pharmacol (2015) 0.84
Intravascular optical imaging of high-risk plaques in vivo by targeting macrophage mannose receptors. Sci Rep (2016) 0.83
Associations of lipid levels susceptibility loci with coronary artery disease in Chinese population. Lipids Health Dis (2015) 0.83
Emodin Inhibits Homocysteine-Induced C-Reactive Protein Generation in Vascular Smooth Muscle Cells by Regulating PPARγ Expression and ROS-ERK1/2/p38 Signal Pathway. PLoS One (2015) 0.83
Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. Arterioscler Thromb Vasc Biol (2015) 0.83
TLR4-mediated inflammation promotes foam cell formation of vascular smooth muscle cell by upregulating ACAT1 expression. Cell Death Dis (2014) 0.83
Yindanxinnaotong, a Chinese compound medicine, synergistically attenuates atherosclerosis progress. Sci Rep (2015) 0.83
Effects of 5-aminolevulinic acid-mediated sonodynamic therapy on macrophages. Int J Nanomedicine (2013) 0.83
Resveratrol counteracts inflammation in human M1 and M2 macrophages upon challenge with 7-oxo-cholesterol: potential therapeutic implications in atherosclerosis. Oxid Med Cell Longev (2014) 0.82
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature (2011) 13.53
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature (2010) 10.60
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 10.55
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest (2007) 9.09
Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 8.65
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Macrophages in the pathogenesis of atherosclerosis. Cell (2011) 7.78
The immune system in atherosclerosis. Nat Immunol (2011) 6.51
Circulating microRNAs in patients with coronary artery disease. Circ Res (2010) 6.28
9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature (2011) 6.25
A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet (2010) 6.07
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol (2009) 5.87
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med (2007) 5.28
A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet (2011) 5.23
MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A (2008) 5.15
Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol (2009) 5.03
Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal (2009) 4.73
ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science (2010) 4.67
Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med (2010) 4.32
The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol (2008) 4.20
Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol (2010) 4.07
Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med (2002) 4.02
Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest (2007) 3.89
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med (2010) 3.79
Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation (2008) 3.69
Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med (2006) 3.65
Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol (2010) 3.53
Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of Apoe-/- and Ldlr-/- mice lacking CHOP. Cell Metab (2009) 3.51
Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med (2009) 3.43
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med (2008) 3.33
Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab (2010) 3.29
Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One (2010) 3.15
Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A (2006) 3.00
NETs: a new strategy for using old weapons. Trends Immunol (2009) 2.98
Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation (2008) 2.98
Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res (2007) 2.85
B cell depletion reduces the development of atherosclerosis in mice. J Exp Med (2010) 2.79
Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation (2010) 2.69
Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation (2008) 2.62
IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest (2004) 2.56
CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood (2008) 2.52
Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest (2011) 2.37
Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol (2008) 2.35
Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab (2010) 2.33
Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A (1999) 2.33
Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol (2010) 2.32
Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med (2006) 2.31
Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity (2004) 2.27
Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res (2007) 2.22
Functional role of CD11c+ monocytes in atherogenesis associated with hypercholesterolemia. Circulation (2009) 2.19
Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med (2009) 2.15
Neutrophil secretion products pave the way for inflammatory monocytes. Blood (2008) 2.12
Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation (2007) 2.06
Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE-/- mice. Thromb Haemost (2007) 2.00
Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2006) 1.99
Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res (2003) 1.99
Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation (2006) 1.95
Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves. J Exp Med (2009) 1.93
Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ Res (2009) 1.88
Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood (2010) 1.86
Genetics of myocardial infarction: a progress report. Eur Heart J (2010) 1.84
T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A (2005) 1.82
Endoplasmic reticulum stress and atherosclerosis. Nat Med (2010) 1.78
Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation (2006) 1.77
Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol (2007) 1.77
Emerging role of Toll-like receptors in atherosclerosis. J Lipid Res (2008) 1.75
Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA (2005) 1.70
Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med (2010) 1.68
LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest (2010) 1.67
GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. J Exp Med (2009) 1.66
Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol (2005) 1.63
Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood (2004) 1.61
Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res (2006) 1.61
CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden. Arterioscler Thromb Vasc Biol (2007) 1.59
Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis (2011) 1.58
Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med (2007) 1.54
Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med (2010) 1.52
The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. J Lipid Res (2008) 1.52
Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab (2011) 1.52
Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation (2007) 1.47
Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest (2011) 1.46
Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res (2009) 1.45
Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci U S A (2008) 1.41
Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol (2009) 1.40
Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation (2005) 1.40
CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest (2011) 1.39
Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions. Arterioscler Thromb Vasc Biol (2006) 1.39
Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov (2010) 1.38
The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol (2005) 1.37
Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J (2009) 1.36
Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal (2009) 4.73
MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest (2012) 1.77
Deficiency of the sialyltransferase St3Gal4 reduces Ccl5-mediated myeloid cell recruitment and arrest: short communication. Circ Res (2014) 1.50
The dark side of EGFP: defective polyubiquitination. PLoS One (2006) 1.49
Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science (2011) 1.30
Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination. Cancer Res (2006) 1.15
Arrest Functions of the MIF Ligand/Receptor Axes in Atherogenesis. Front Immunol (2013) 0.94
The use of high-throughput technologies to investigate vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol (2012) 0.90
Catching up with important players in atherosclerosis: type I interferons and neutrophils. Curr Opin Lipidol (2011) 0.83
Endothelial CSN5 impairs NF-κB activation and monocyte adhesion to endothelial cells and is highly expressed in human atherosclerotic lesions. Thromb Haemost (2013) 0.81
ApoE controls the interface linking lipids and inflammation in atherosclerosis. J Clin Invest (2011) 0.80
MicroRNAs: from basic mechanisms to clinical application in cardiovascular medicine. Arterioscler Thromb Vasc Biol (2013) 0.76
Fractalkine as an important target of aspirin in the prevention of atherogenesis : Editorial to: "Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice" by H. Liu et al. Cardiovasc Drugs Ther (2010) 0.76
Potential cell-specific functions of CXCR4 in atherosclerosis. Hamostaseologie (2015) 0.75